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Abstract
Background: Eisenmenger’s syndrome (ES) consists of pulmonary hypertension with a reversed or bidirectional
shunt at the atrioventricular, or aortopulmonary level.
The cardiovascular changes that occur during the pregnancy contribute to the high maternal morbidity and
mortality in patients with ES. This study is to assess maternal and fetal outcomes in patients with ES.
Methods: This study is a retrospective analysis of 11 pregnancies in women with ES who delivered at a tertiary care
center in west China between 2010 and 2014. Cases were divided into group I (maternal survival) and group II
(maternal death). Clinical data were noted and analyzed.
Results: All ES patients presented with severe pulmonary arterial hypertension (PAH). Four maternal deaths were
recorded (maternal mortality of 36%). Only one pregnancy continued to term. Ventricular septal defect diameter in
group II was larger than that in group I (2.93 ± 0.76 cm vs. 1.90 ± 0.54 cm, p < 0.05). Arterial oxygen saturation and
pre-delivery arterial oxygen tension during oxygen inhalation were significantly lower in group II (p < 0.05).
Pulmonary arterial blood pressure (PABP) in both groups were high while ejection fractions (EF) were significantly
lower in group II (p < 0.05). The incidence of pre-delivery heart failure in group II was substantially higher than in
survivors (100 vs.14.3%, p < 0.05). Fetal complications were exceptionally high: preterm delivery (88%), small for
gestational age (83%), fetal mortality (27%) and neonatal mortality (25%).
Conclusions: In west China,the perinatal outcome of pregnant women with ES is poor, especially when
complicated with high pulmonary arterial hypertension (PAH). Pregnancy remains strongly contraindicated in ES.
Effective contraception is essential, and the option of terminating pregnancy in the first trimester should be
presented to pregnant women with ES.
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Background
Eisenmenger’s syndrome (ES) consists of pulmonary
hypertension with a reversed or bidirectional shunt at
the atrioventricular, or aortopulmonary level. It was first
described in 1897 by Victor Eisenmenger in a single pa-
tient and in 1958 Paul Wood provided further data in a
large patient population with congenital heart defects
[1]. Congenital heart defects that may result in
Eisenmenger’s syndrome include ventricular septal
defect (VSD), atrioventricular septal defect (AVSD) or
atrioventricular canal defect (AVCD), patent ductusarter-
iosus (PDA), atrial septal defect (ASD), D-transposition of
the great vessels, and surgically created aortopulmonary
connections. The likelihood of developing ES depends on
the size and location of the intracardiac defect [2]. ES
gradually leads to progressive right ventricular (RV) failure
with digital clubbing, cyanosis, dyspnea, edema, a loud
pulmonary component of second heart sound on auscul-
tation, right ventricular hypertrophy in electrocardiog-
raphy, and arrhythmias.
Although ES progresses slowly, patients have a poor
quality of life. The increased circulatory burden in
gravid patients contributes to high maternal mortality
rates (30–50%) in pregnancy in ES [3–7]. The major
causes of death in ES are right ventricular failure,
pulmonary hypertension crisis, arrhythmia, and stroke.
Despite modern developments in obstetric medicine and
cardiovascular interventions, the prognosis of pregnancy
with ES has not improved greatly, and this is particularly
so in low income countries. ES is class IV in the WHO
pregnancy risk classes and is regarded as contraindication
for pregnancy [8]. Meanwhile, fetal outcomes are also
poor, with a high risk of spontaneous abortion, intrauter-
ine growth restriction (IUGR), preterm birth, low-birth
weight and congenital cardiac malformations [9].
However, some women with ES do conceive. Termin-
ation of pregnancy is generally recommended for those
who present early in the pregnancy. There are few re-
ports of ES in pregnancy from high income countries
and less from low income countries, especially studies
examining with aggressive pulmonary arterial hyperten-
sion (PAH). The present study reviews perinatal out-
comes and management of women with ES in pregnancy
with aggressive PAH in west China.
Methods
This was a retrospective study. Approval was obtained
from the Institutional Review Board of West China
Second University Hospital. Medical records were
reviewed of pregnant women with congenital heart dis-
ease (CHD) who were admitted during 2010 to 2014 to
West China Second University Hospital, the regional
tertiary referral center.
Subjects
Eleven pregnant women with ES admitted to the hos-
pital were identified in CHD pregnants. The majority of
the patients had been transferred from other local hospi-
tals. We received written permission from the patient or
relatives to use the medical records, the images and the
patients’ information. Cases were retrospectively divided
into two groups, group I (maternal survival, 7 cases) and
group II (maternal death, 4 cases).
Management of ES
After admission, patient evaluation was performed by a
multidisciplinary team, consisting of obstetrician, midwife,
cardiologist, anesthetist, intensive care physician and neo-
natologist. Complete general physical, cardiovascular, and
obstetric examination were performed. New York Heart
Association (NYHA) class was assigned. Laboratory inves-
tigations were undertaken.
Bedrest and oxygen therapy were provided. Oxygen
was administered by mask at 5 L/min. A variety of di-
uretics were used if necessary. The status of the mother
and fetus was closely monitored. Patients were evaluated
by obstetricians, cardiologist and intensive care phys-
ician daily. Ultrasound scans and cardiotocography
(CTG) were performed daily to evaluate fetal status.
Worsening of maternal clinical condition, labor or fetal
distress were indications for delivery. Arterial, central
venous, and/or pulmonary artery monitoring were per-
formed to optimally manage the mother. Hemodynamic
measurements and blood gas analyses were carried out
in all cases upon admission, during treatment, and after
delivery. Antibiotic prophylaxis was provided for endo-
carditis prophylaxis.
Data collection
Maternal baseline data reviewed included age, parity,
preconception body weight and height, place of resi-
dence, education level, nature of underlying cardiac le-
sion, treatment and cardiac surgery before pregnancy,
and results of routine examination during pregnancy.
Cardiac functional class and heart failure category
(American NYHA) after admission were noted. Cardiac
lesion size, ejection fraction (EF), reversed or bidirec-
tional shunt at the atrioventricular or aortopulmonary
level, and pulmonary arterial blood pressure (PABP)
were acquired from echocardiography and Doppler car-
diographic examination upon admission. Arterial oxygen
saturation, arterial oxygen tension and hemoglobin (Hb)
were noted upon admission. Mode of delivery,
anesthesia options, operative time and blood loss were
also reviewed.
Fetal parameters including birth weight, Apgar score,
fetal death or neonatal death were studied.
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Statistical analyses
Parameters were analyzed using Chi-squared test,
Fisher’s exact test, two-tailed student’s t-test and Mann-
Whitney U test. P- value < 0.05 was considered statisti-




Subjects were 11 pregnant patients who were diagnosed
with ES. All cases were singleton pregnancies. Mean ma-
ternal age was 25.7 years (range: 17–35 years). Mean
weeks of gestation at admission was 32+5 weeks (range:
21–39+1 weeks). Pre-conception body height and weight
were 156.5 cm (range: 150–166 cm) and 57.5 kg (range:
46–69 kg). In group I (surviving mothers), six patients
(out of seven) had history of prior pregnancy, with two
live births. Three out of the four patients in group II had
a history of prior pregnancy and delivery. The incidence
of prior delivery history of group II was significantly
higher than that of group I (p < 0.05).
CHD in three cases (two in group I and one in group
II) were not identified until admission to the local
hospital. Among the eleven cases, eight patients (five in
group I, and three in group II) knew about their CHD
but refused to visit the cardiologist regularly, and refused
pre-conception counseling by obstetrician and cardiolo-
gist, and there was no pre-pregnancy hemodynamic data.
Among eight patients, only two patients (city residents)
received regular cardiologist and obstetric care during
pregnancy, and both refused abortion despite of know-
ledge about the risks and prognosis. Nine patients had
no regular care,all derived from the rural area. None of
the patients had undergone cardiac surgery before preg-
nancy. In regard to education level, one patient gradu-
ated from junior college, one was illiterate, and the
others had finished middle school or primary school.
Maternal characteristics of all patients in the study are
shown in Table 1.
Cardiac characteristics
In group I, five cases had VSD and two cases ASD; one
patient had heart failure (HF). During admission, mean
pulmonary arterial blood pressure (PABP) was 102 ±
27 mmHg (range: 77–139 mmHg); mean ejection frac-
tion (EF) was 64 ± 1.3% (range: 62–66%); mean arterial
oxygen saturation and tension under oxygen inhalation
was 80 ± 6% (range: 74–90%), and 46.6 ± 3.0 mmHg
(range: 43–51 mmHg) respectively; mean hemoglobin
was 131 ± 11.6 g/L (range: 119–150 g/L).
In group II, all cases had VSD with HF. Upon admission,
mean PABP was 101 ± 22 mmHg (range: 78–128 mmHg);
mean EF 51 ± 11% (range: 35–60%); mean arterial oxygen
saturation and tension under oxygen inhalation was 63 ±
3% (range: 60–67%) and 40 ± 1.4 mmHg (range: 38–
41 mmHg) and mean hemoglobin was 124 ± 11 g/L
(range: 107–130 g/L). Detailed information is shown in
Table 2.
In this study, 9/11 patients had VSD. The cardiac lesion
diameter of VSD in group II was significantly larger than
that in group I (2.93 ± 0.76 cm vs. 1.9 ± 0.54 cm, p < 0.05).
The incidence of HF in group II was significantly higher
than that in group I (100 vs. 14.3%, p < 0.05); arterial
oxygen saturation and arterial oxygen tension under
oxygen inhalation were significantly lower in group II (p <
0.05). Meanwhile, we found that PABP in both groups
were high, and EF were significantly lower in group II
(p = 0.008). Clinical cardiac data are shown in Table 2.
Complications
In group I, after delivery, one patient had pulmonary in-
fection (PI) and one patient had severe preeclampsia
Table 1 Maternal characteristics




Age of patient when
CHD diagnosed
1 28 166 59 Rural Middle school N N 36+4 8 years old
2 29 160 50 Rural Middle school N N 21 9 gestational weeks
3 29 160 69 Rural Illiterate N N 29+5 18 years old
4 28 150 46 Rural Primary school N N 30+2 29+3 gestational weeks
5 21 155 66 Rural Middle school N N 39+1 1 year old
6 25 157 64 Urban Junior college Y N 35+5 10 years old
7 20 152 53.5 Urban Middle school Y N 29+5 1 year old
8 17 160 55 Rural Middle school N N 34+2 3 years old
9 35 155 63.5 Rural Primary school N N 36 35+5 gestational weeks
10 25 150 55 Rural Middle school N N 34 19 years old
11 26 156 51 Rural Primary school N N 33+4 2 years old
GA gestational weeks, CHD congenital heart defect. Boldface: Group II patients (maternal death)
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(SP). In group II, three patients had PI, two patients had
SP. The tendency to PI and hypertensive disorders in
pregnancy were higher in group II, although not reach-
ing statistical significance (Table 3).
Clinical outcomes
Perinatal clinical data are shown in Table 4. There were
four patients admitted for induction before 32 gesta-
tional weeks in group I: two because of fetal demise
(FD) and one for fetal hydrocephalus. No case in group
II delivered before 32 gestational weeks.
In group I, six patients underwent CS and one patient
had induced vaginal delivery (at 21 gestational weeks, for
fetal demise). In group II, three patients underwent CS
and one mother died before delivery. CS was performed
under general anesthesia in six cases, three cases under
epidural anesthesia. Mean operation time and measured
blood loss at surgery did not significantly differ between
the two groups. Details are shown in Table 4.
Four maternal deaths occurred in our study; overall
mortality was 36.4% (4/11). Case #8 was diagnosed with
VSD at three years of age following routine examination.
Her family refused cardiac surgery and there was no
regular follow-up by a cardiologist. Her cardiac condi-
tion progressed to ES two years before pregnancy. Dur-
ing this, her first, pregnancy, she was transferred to our
hospital at 34+2 weeks for acute heart failure, with severe
preeclampsia and thrombocytopenia. Her ECG showed
sinus tachycardia with right axis deviation (+129°), sug-
gesting bilateral atrial enlargement and ventricular
hypertrophy. With HF treatment and preoperative prep-
aration, emergency CS for fetal distress was performed
on the admission day under general anesthesia. After de-
livery, she rapidly developed severe pulmonary infection
and uncontrollable heart failure, and died one day after
operation. Her baby is healthy.
Case #9 was diagnosed to have VSD just two days ago
before admission. She had one term vaginal delivery nine
years earlier, and that baby is alive without abnormal
manifestations. She had no care in this current
pregnancy and was admitted at 36 weeks with severe
preeclampsia and heart failure. Her ECG showed sinus
tachycardia with right bundle branch block and right
axis deviation (+264°), suggesting right ventricular hyper-
trophy and bilateral atrial enlargement. She died before
delivery on the day of admission, resulting from uncon-
trollable heart failure. Her fetus died in utero.
Cases #10 and #11 were similar to the 8th case, in that
they had received no cardiac treatment or follow-up.
Neither received cardiologist or obstetrician care during
this pregnancy. Case #10 had one vaginal delivery four
years earlier, in which the baby died due to prematurity.
Case #11 had one CS seven years earlier (birth weight
2500 g) and that baby is alive without any abnormality.
In addition, Case #11 had one induction six years earlier
at 17 gestational weeks for FD, and two abortions. They
were admitted into our hospital respectively at 34 and
33+4 gestational weeks for heart failure with severe PAH.
Upon admission, they were both found to have large
VSD’s and had progressed to ES. The ECG of Case #10
after admission showed sinus rhythm with left bundle
branch block and left axis deviation (−62°), suggesting
left atrial enlargement and right ventricular hypertrophy.
The ECG of Case #11 showed sinus rhythm, complete
right bundle branch block with first degree atrioven-
tricular block, right ventricular hypertrophy and left
atrial enlargement. Emergency CS under general
anesthesia was performed on the day of admission in
both patients because of labor. After delivery, to treat se-
vere pulmonary infection and heart failure, both mothers
were supported with ventilators. However, both died
three days after operation. Post-mortem examination
Table 2 Maternal cardiac characteristics
Case Cardiac lesion Lesion diameter (cm) EF (%) PABP (mmHg) Arterial oxygen saturation (%) Arterial oxygen tension (mmHg) Hb (g/l)
1 VSD 1.4 64 100 90 51 150
2 ASD* 3.0 62 95 76 46 140
3 VSD 1.9 63 84 79 47 124
4 VSD 1.8 64 139 74 45 137
5 ASD 2.1 66 77 87 50 125
6 VSD 1.6 65 139 78 44 119
7 VSD 1.5 63 78 75 43 121
8 VSD 2.9 57 88 64 38 107
9 VSD 2.5 52 110 67 41 128
10 VSD 4.0 35 128 62 41 129
11 VSD 2.3 60 78 60 40 130
VSD ventricular septal defect, ASD atrial septal defect, ASD* ASD with patent ductus arteriosus, Hb hemoglobin, EF ejection fraction. Boldface: Group II patients
(maternal death)
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was refused. Their babies both survived without any ab-
normal manifestation.
No fetus had congenital heart defects in the study.
Two fetal deaths occurred at 21 and 29+5 gestational
weeks in group I and one fetal death at 36 gestational
weeks due to maternal death in group II. There were
eight live births in the study; seven preterm, and one
term birth; two neonates died within one week after
birth for prematurity,six babies survived until now. The
incidence of fetal mortality, preterm delivery and neo-
natal mortality was 27.27% (3/11), 87.5% (7/8) and 25%
(2/8) respectively. The incidence of small for gestational
age (SGA) [10] was 83.33% (5/6) of the live babies, one
with congenital hydrocephalus, five with no persistent
abnormality until now. Fetal outcomes are presented in
Table 4.
Discussion
Pregnancy is well known to require significant
hemodynamic changes in women to meet the rising
metabolic demands of the mother and the fetus. The
cardiovascular changes that occur during the pregnancy
contribute to the high maternal morbidity in patients
with Eisenmenger’s syndrome, including heart failure,
dyspnea, syncope and sudden death. Therefore, ES is
regarded as an absolute contraindication for pregnancy
[8]. If a woman with ES chooses to continue with preg-
nancy, oxygen therapy, aggressive use of pulmonary
vasodilator therapies, and care by a specialist multidis-
ciplinary team may help to minimize mortality [11].
In this study, most patients with ES were rural resi-
dents in west China, with low educational level and poor
physical status. They suffered from cardiac lesions over a
long period with chronic tolerance to CHD, or no symp-
toms. Perhaps as a result of lack of general and special
medical knowledge, these rural patients all refused car-
diac surgery and were not followed up by cardiologists.
Table 3 Maternal clinical data
Case Maternal
complications
History of pregnancy Maternal
Death
1 HF, ICP, PI 1st pregnancy: abortion;
2nd pregnancy: abortion
N
2 – 1st pregnancy: abortion;
2nd pregnancy: CS for massive
hemorrhage during labor







1st pregnancy: CS 11 years
earlier with birth weight
3250 g and healthy baby
2nd pregnancy: abortion
N
4 – 1st pregnancy: premature
delivery 6 years earlier,





1st pregnancy: abortion N
6 left thoracic
deformity




8 HF, SP, PI none Y
9 HF, SP 1st pregnancy: term vaginal
delivery 9 years earlier and
baby healthy till now
Y
10 HF, PI 1st pregnancy: vaginal delivery
4 years earlier and baby died
(prematurity)
Y
11 HF, PI 1st pregnancy: CS 7 years earlier
with birth weight 2500 g, baby alive
2nd pregnancy: induction at 17




ICP intrahepatic cholestasis of pregnancy, PI pulmonary infection, HF heart
failure, SP severe preeclampsia, PA placental adhesion, PE
pulmonary embolism
Table 4 Delivery data and fetal outcomes
Case Mode of delivery Operative time Operative blood loss GA at delivery Anesthesia Fetal outcome Birth weight Newborn outcome
1 CS 38 min 250 ml 36+5 Epidural SGA 1740 g live
2 Induction /- / 21 / FD 370 g /
3 CS 35 min 200 ml 29+6 General SGA 920 g dead
4 CS 60 min 300 ml 30+3 General SGA 970 g dead
5 CS 48 min 220 ml 39+2 Epidural SGA 1825 g live
6 CS 43 min 300 ml 36 General SGA 2045 g live
7 CS 55 min 200 ml 29+5 General FD 680 g /
8 CS 42 min 270 ml 34 General SGA 1690 g live
9 CS 30 min 150 ml 34+2 General SGA 1630 g live
10 DBD /- /- 36 /- FD /- /
11 CS 28 min 260 ml 33+4 Epidural / 1720 g live
DBD maternal death before delivery, FD fetal demise, SGA small for gestational age; Boldface: Group II patients (maternal death)
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Most of them were not sufficiently conscious of the in-
creased risks and mortality of pregnancy with ES, and
there was lack of pre-conception counseling nor regular
care with the cardiologist and obstetrician during
pregnancy. Although early pregnancy termination was
recommended for patients with known ES, none of them
chose to discontinue pregnancy in the first trimester.
After 32 gestational weeks, the hemodynamic burden of
pregnancy peaks, with the highest risk for maternal and
fetal life, especially in the presence of a large VSD. In
this study, five cases with heart failure presented at this
stage, and four of those women eventually died with un-
controllable heart failure.
From this study, we found that patients with pulmon-
ary infection and/or SP were more likely to succumb to
heart failure and death. Such complications likely further
exacerbate cardiovascular and pulmonary vascular de-
mands. In our study, PABP in all patients was very high.
Pulmonary hypertension is associated with high morbid-
ity and mortality during pregnancy. For patients with ag-
gressive PAH in pregnancy, hypertension reduction
using sildenafil or prostacyclin analogs has not been the
primary therapeutic regimen because of associated ad-
verse effects [12]. However, Rao et al. deemed that for
women with pulmonary hypertension who do become
pregnant and do not wish to terminate pregnancy, it is
important to continue pre-pregnancy management such
as anticoagulation, prostacyclin analogs, and sildenafil
[13]. Because of limited evidence with only a few pub-
lished case series, there is no consensus on the use of
such therapies for ES patients in pregnancy. In our hos-
pital, sildenafil or prostacyclin analogs were not given to
ES patients with aggressive PAH throughout pregnancy.
Although large intrapulmonary thrombi occur in up to a
quarter of patients with Eisenmenger syndrome, no evi-
dence of thrombi was identified in our study and no
anticoagulation was performed.
Close pregnancy monitoring and supportive care for
these patients are essential, especially for cases with ag-
gressive PAH. To monitor cardiac and hemodynamic
status of ES patients, arterial line, central venous cath-
eter or right-sided catheterization may be of use. How-
ever, invasive monitoring is not routinely recommended
to pregnant women because of the increased risk of pul-
monary artery rupture or thrombosis, unless the patient
is unstable or with high-risk lesions. Therefore, monthly
echocardiograms and weekly examination for these
women are needed. If PABP aggravates during early tri-
mester, the prognosis of continuing pregnancy may be
particularly bad, and therapeutic abortion is recom-
mended. If these patients insist on continuing preg-
nancy, hospitalization in the second trimester is highly
recommended [14]. They should be admitted in a ter-
tiary center, with a multidisciplinary team approach.
Due to few reports, it should be noted that the ideal
mode of delivery in ES patients with PAH is controver-
sial [7, 15]. Compared with cesarean delivery, although
vaginal delivery is associated with less risk of haemor-
rhage, infection and venous thromboembolism, vaginal
delivery is associated with increased basal cardiac output
and increased output with every uterine contraction,-
which would promote cardiac arrhythmia and worsen
heart failure. Furthermore, ES patients with PAH will be
delivered early due to serious disease condition with un-
favourable cervix and labour induction is likely to be dif-
ficult in these patients. Advantages of cesarean delivery
include that time and opportunity of delivery can be
controllable, and presence of senior staff can usually be
ensured [16, 17]. Since our cases had ES with high PAH,
we thought CS was suitable; our cases in third trimester
were all delivered by cesarean section, except for one
death before delivery. As far as blood loss and time of
operation were concerned, no case lost more than
300 ml and all operations were completed within an
hour. Because of the greater stability of hemodynamics,
CS may be safer than vaginal delivery for these patients
with severe baseline hemodynamic abnormalities.
In our study, 6/9 ES patients underwent CS under gen-
eral anesthesia, whereas most of the previous reported ES
patients were given epidural anesthesia or combined
spinal epidural anesthesia [16, 18]. Either epidural or gen-
eral anesthesia has been used with successful outcomes.
Gurumurthy et al. reported general anesthesia in patient
with ES undergoing cesarean section [19]. We hold to the
same opinion as Gurumurthy’s: general anesthesia could
allow for adequate control of pain and early initiation of
thromboprophylaxis. Moreover, it allows for placement of
an esophageal ultrasound probe after trachea cannulation
for ultrasonic monitoring.
The presence of maternal cardiovascular disease places
the fetus and neonate at greater risk. Increased rates of
miscarriage, SGA, prematurity, intrauterine fetal demise,
and neonatal death are present in many forms of mater-
nal CHD whether repaired or unrepaired [20]. ES with
PAH in pregnancy presents an increased risk of fetal
complications such as stillbirth, SGA and preterm deliv-
ery [6]. Our study supports these findings and suggests
that severe PAH in ES patients is likely to cause even
higher risk. Our findings support that ES patients with
severe PAH should be counseled regarding the discour-
aging outcomes and options for termination, especially
in low income countries as reported by Lin et al. [21].
More women with ES are surviving in recent years be-
cause of advances in medicine and neonatal care. How-
ever, the prognosis for a pregnant woman with ES has
not improved. Gleicher et al. reviewed 44 published
cases and 52% pregnancy-associated mortality with ES,
with 36.1% mortality on first pregnancy, 26.7% on
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second pregnancy and 33.3% on third pregnancy [4].
Our study indicated that the maternal mortality was 50%
on first pregnancy, 50% on second pregnancy and the
delivery frequency was higher in group II. Drenthen et
al. reported that in pregnant ES patients, the occurrence
of heart failure was 21%, prematurity rate 64.7%, SGA
37.5%, fetal mortality 9.5 %, and death within the first
year of life 18.2% [22]. Stoddart et al. reviewed 30 cases
and found that maternal mortality was 39%; the inci-
dence of preterm deliveries, perinatal death, and total
fetal wastage was respectively 44, 14 and 44% [23].
Alvira et al. reported maternal mortality was 33% ac-
cording to a prospective study of 12 cases [5]. Yentis et
al. studied 15 cases and identified that maternal mortal-
ity, fetal mortality and prematurity rate was respectively
40, 8 and 85% [6]. In our study, the incidence of mater-
nal HF, maternal mortality, preterm birth, SGA, fetal
mortality and neonatal mortality were respectively 45,
36, 88, 83, 27 and 25% respectively. Our maternal out-
comes were similar to the other reports, whereas fetal
outcome was worse than other reports. Most of our
cases were from the rural areas of west China where
there is a less developed medical system, and rejection
of regular prenatal care with obstetricians and cardiolo-
gists is common. The development of SP may be an add-
itional risk factor in ES. Phupong et al. recently
performed a small review of five cases of ES with pre-
eclampsia, and found that maternal mortality and pre-
mature delivery rate were respectively 80 and 60% [24],
substantially higher than those without SP. Wang and
Liu presented four cases of pregnancy complicated with
HELLP syndrome in the setting of ES: three of the
mothers died [25]. In our study, the incidence of SP in
group II (maternal death) was higher than group I. It
seems highly likely that SP or HELLP may aggravate the
dangers of pregnancy in ES.
There have been few reports suggesting particular suc-
cess in pregnancy with ES. Wang et al. recently reported
perinatal outcome in 13 cases with ES and found mater-
nal mortalityto be 7.7% (1/13), while infant loss was
38.5% and prematurity rate was 100%. The only mater-
nal death occurred 17 days after delivery etc., resulting
from HELLP syndrome, lung infection and heart failure
[16]. However, optimistic reports of maternal survival
rates are rare. We think in Wang’s study the lower
maternal mortality may result from the higher deliv-
ery rate before 28 weeks (38.5%; 5/13). The progres-
sive hemodynamic changes from second trimester to
the third trimester add to the burden of a compro-
mised right ventricle. Further studies with more cases
will be needed to confirm this. In our study, 76.9%
(10/11) cases delivered beyond 28 weeks’gestation and
the maternal mortality rate was 36%, similar to other
reports.
Conclusion
In conclusion, the present study examined perinatal out-
comes and management of women with ES in pregnancy
with aggressive PAH in west China. Timely diagnosis
and treatment of these patients’ underlying cardiac le-
sion in early childhood are critical for their pregnancy
and delivery. Pregnancy in ES, especially complicated
with aggressive PAH, is still associated with high mater-
nal and fetal morbidity and mortality. Effective precon-
ception counseling is essential, and termination of
pregnancy in first trimester advisable. Risks will increase
significantly in pregnancy continued into the third tri-
mester. If the ES patient with PAH wishes to continue
pregnancy, they should be monitored closely and managed
in a tertiary center with collaborative efforts among obste-
tricians, cardiologists, anesthesiologists, pediatricians and
intensivists. There is no standardized approach to man-
agement of ES in pregnancy; successful perinatal out-
comes seem heavily dependent on the individualization of
treatment for each patient.
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